Blue Trust Inc. Increases Holdings in Jazz Pharmaceuticals PLC $JAZZ

Blue Trust Inc. increased its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 6.8% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,152 shares of the specialty pharmaceutical company’s stock after buying an additional 200 shares during the period. Blue Trust Inc.’s holdings in Jazz Pharmaceuticals were worth $334,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Philip James Wealth Mangement LLC increased its stake in shares of Jazz Pharmaceuticals by 42.0% during the 2nd quarter. Philip James Wealth Mangement LLC now owns 15,797 shares of the specialty pharmaceutical company’s stock worth $1,676,000 after purchasing an additional 4,675 shares during the last quarter. State of Alaska Department of Revenue increased its stake in shares of Jazz Pharmaceuticals by 75.1% during the 2nd quarter. State of Alaska Department of Revenue now owns 57,933 shares of the specialty pharmaceutical company’s stock worth $6,147,000 after purchasing an additional 24,850 shares during the last quarter. Envestnet Portfolio Solutions Inc. increased its position in Jazz Pharmaceuticals by 38.9% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 4,369 shares of the specialty pharmaceutical company’s stock worth $542,000 after buying an additional 1,223 shares during the last quarter. Inspire Investing LLC purchased a new stake in Jazz Pharmaceuticals in the first quarter worth $689,000. Finally, Baird Financial Group Inc. purchased a new stake in Jazz Pharmaceuticals in the first quarter worth $539,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insider Buying and Selling

In related news, Director Bruce C. Cozadd sold 6,000 shares of the business’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total transaction of $771,720.00. Following the completion of the transaction, the director directly owned 429,973 shares in the company, valued at $55,303,127.26. The trade was a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 11,500 shares of company stock worth $1,525,280 in the last three months. 4.30% of the stock is owned by insiders.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock opened at $135.14 on Tuesday. The firm’s 50 day simple moving average is $126.25 and its 200 day simple moving average is $115.66. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. The firm has a market capitalization of $8.20 billion, a PE ratio of -20.08, a price-to-earnings-growth ratio of 8.32 and a beta of 0.28. Jazz Pharmaceuticals PLC has a 1-year low of $95.49 and a 1-year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing analysts’ consensus estimates of ($5.61) by ($2.64). The firm had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The firm’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter last year, the firm earned $5.30 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. As a group, analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Analyst Ratings Changes

JAZZ has been the subject of several recent research reports. Weiss Ratings reissued a “sell (d)” rating on shares of Jazz Pharmaceuticals in a report on Wednesday, October 8th. Morgan Stanley lifted their target price on shares of Jazz Pharmaceuticals from $163.00 to $167.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 24th. Zacks Research upgraded shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, August 15th. The Goldman Sachs Group lifted their target price on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a “buy” rating in a research note on Friday, August 29th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, August 28th. Fourteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $178.93.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.